Course of irritable bowel syndrome associated with small intestinal bacterial overgrowth
DOI: 10.32364/2587-6821-2022-6-5-232-236
Yu.A. Kulygina, M.F. Osipenko
Novosibirsk State Medical University, Novosibirsk, Russian Federation
Aim: to assess the rate and pattern of the clinical course of small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS).
Patients and Methods: this study enrolled 100 patients aged 18–68 (mean age 33.5 [26; 46.25] years) with established IBS. The patients were divided into two groups. The IBS with diarrhea (IBS+D) group included 54 patients (mean age 36 [23.0; 49.5] years). The IBS without diarrhea (IBS–D) group included 46 patients (mean 37 [24.5; 49.5] years). All patients underwent lactulose hydrogen breath test using Gastroplus+ monitor to establish SIBO. A positive lactulose hydrogen breath test (a rise of ≥20 ppm by 90 min with dual-peak profile or a steady growth of ≥12 ppm from baseline in hydrogen) suggested SIBO. Medical history, clinical and lab tests, and the parameters of the quality of life (QoL) using SF-36 and QOL questionnaires were evaluated.
Results: the occurrence of SIBO in patients with IBS was 32%, i.e., 37% in the IBS+D group and 28% in the IBS–D group. Multivariate analysis has demonstrated that flatulence in IBS increases the chances of having SIBO by 110.9 times. Univariate analysis revealed universal clinical associations of SIBO with bloating, flatulence, nausea, weakness, tearfulness, and irritability in IBS. Hepatic steatosis is typical for IBS with SIBO (OR=1.75, 95% CI 1.01–3.99, p=0.037). The use of loperamide in IBS+D is associated with a 2.2-fold increase in SIBO risk. SIBO in IBS is associated with a reduction in QoL, as demonstrated by most SF-36 scales (physical and emotional health) and QOL.
Conclusions: SIMO in IBS mimics exacerbation, thereby resulting in the prescription of inadequate treatment.
Keywords: irritable bowel syndrome, small intestinal bacterial overgrowth, hydrogen respiratory test, quality of life.
For citation: Kulygina Yu.A., Osipenko M.F. Course of irritable bowel syndrome associated with small intestinal bacterial overgrowth. Russian Medical Inquiry. 2022;6(5):232–236 (in Russ.). DOI: 10.32364/2587-6821-2022-6-5-232-236.
About the authors:
Yuliya A. Kulygina — assistant of the Department of the Propaedeutics of Internal Diseases, Novosibirsk State Medical University; 52, Krasnyi av., Novosibirsk, 630091, Russian Federation; ORCID iD 0000-0002-4202-9130.
Marina F. Osipenko — Head of the Department of the Propaedeutics of Internal Diseases, Novosibirsk State Medical University; 52, Krasnyi av., Novosibirsk, 630091, Russian Federation; ORCID iD 0000-0002-9696-1302. Contact information: Yuliya A. Kulygina, e-mail: yu_blinova@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 27.03.2022.
Revised 19.04.2022.
Accepted 18.05.2022.
2. Gaus O.V, Livzan M.A., Osipenko M.F. Irritable bowel syndrome: how to avoid mistakes? Pharmateca. 2020;27(2):75–79 (in Russ.). DOI: 10.18565/pharmateca.2020.2.75-79.
3. Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome — An Update. Front Psychiatry. 2020;11:664–669. DOI: 10.3389/fpsyt.2020.00664.
4. Rezaie A., Buresi M., Lembo A. et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775–784. DOI: 10.1038/ajg.2017.46.
5. Pimentel M., Saad R.J., Long M.D., Rao S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115:165–178. DOI: 10.14309/ajg.0000000000000501.
6. Osipenko M.F., Skalinskaya M.I., Kulygina Y.A. et al. What we know about bacterial overgrowth syndrome. Medical Council. 2016;9:70–74 (in Russ.). DOI: 10.21518/2079-701X-2016-9-70-74.
7. Livzan M.A., Osipenko M.F Syndrome of intersection of functional diseases of the digestive tract. RMJ. 2012;20(15):768–770 (in Russ.).
8. Zhuang X., Xiong L., Li L. et al. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:28–38. DOI: 10.1111/jgh.13471.
9. Akhmedov V.A., Orlov I.N., Gaus O.V. Modern methods of rehabilitation of patients with irritable bowel syndrome. Therapiya. 2017;3(13):49–55 (in Russ.).
10. Moayyedi P., Mearin F., Azpiroz F. et al. Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice. United Eur Gastroenterol J. 2017;5:773–788. DOI: 10.1177/2050640617731968.
11. Gaus O.V., Livzan M.A. IBS: what do we know about the symptoms today? Consilium Medicum. 2019;21(8):42–48 (in Russ.). DOI: 10.26442/20751753.2019.8.190512.
12. Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N Engl J Med. 2017;376:2566–2578. DOI: 10.1056/NEJMra1607547.
13. Rezaie A., Heimanson Z., McCallum R., Pimentel M. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. Am J Gastroenterol. 2019;114(12):1886–1893. DOI: 10.14309/ajg.0000000000000444.
14. Gupta A., Chey W.D. Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients? Am J Gastroenterol. 2016;111(3):305–306. DOI: 10.1038/ajg.2016.32.
15. Lins L., Carvalho F.M. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4(4):1–12. DOI: 10.1177/2050312116671725.
16. Rodriguez F. Quality of life in patients with irritable bowel syndrome. Psychology in Spain. 2003;7(1):66–76.
17. Shah A., Talley N.J., Jones M. et al. Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020;115:190–201. DOI: 10.14309/ajg.0000000000000504.
18. Purssell H., Whorwell P.J., Athwal V.S., Vasant D.H. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? World J Hepatol. 2021;13(12):1816–1827. DOI: 10.4254/wjh.v13.i12.1816.
19. Shin A., Xu H., Imperiale T.F. Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults. BMJ Open Gastroenterol. 2019;6:e000322. DOI: 10.1136/bmjgast-2019-000322.
20. Singh S.P., Kar S.K., Panigrahi M.K. et al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. Trop Gastroenterol. 2013;34:144–152. DOI: 10.7869/tg.118.
21. Jones-Pauley M., Franco L., Tamimi O. et al. Irritable bowel syndrome symptoms in non-alcoholic fatty liver disease patients are an indicator of depression and anxiety. Gastroenterology. 2020;158(6):S1429. DOI: 10.1016/S0016-5085(20)34239-6.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
